Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 20

  • 591 clinical trials
  • 223 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease64Bladder cancer55Transitional cell carcinoma47Renal cell carcinoma42Bladder transitional cell carcinoma34IgA nephropathy24Acute kidney injury21Non-small cell lung cancer19Urinary tract infection19Lupus nephritis18Clear cell renal cell carcinoma17Paroxysmal nocturnal haemoglobinuria17Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

591 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

591 clinical trials

Chronic kidney disease

Not yet recruiting

Dapagliflozin and SC0062 in adults with type 1 diabetes and chronic kidney disease: effect on albuminuria in a Phase 2 randomized trial

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Transitional cell carcinoma

Not yet recruiting

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Paroxysmal nocturnal haemoglobinuria+1

Not yet recruiting

Long‑Term Safety and Tolerability of Oral Iptacopan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria or IgA Nephropathy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Urinary tract infection

Not yet recruiting

Proof-of-Concept Study of Immune Tests After StroVac (drug combination) Vaccination in Adults with Urinary Tract Infections

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Urinary tract infection

Not yet recruiting

Effect of Pivmecillinam vs Placebo on Enterobacterales Urinary Tract and Bloodstream Infections in High‑Risk Kidney Transplant Recipients (Months 1‑6)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Rigshospitalet

Bladder transitional cell carcinoma stage I

Not yet recruiting

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

IgA nephropathy

Not yet recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx

Bladder cancer

Not yet recruiting

Feasibility of Photodynamic Diagnosis Using Intravesical Hexaminolevulinate with Sub‑One‑Hour Instillation in Patients with Primary or Recurrent Papillary Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hexaminolevulinate
  • Sponsor:Institut Paoli-Calmettes

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Clear cell papillary renal cell carcinoma

Not yet recruiting

Study of Sacituzumab Tirumotecan in Patients with Papillary Renal Cell Carcinoma and Variant Histology Urothelial Carcinoma (Rare Genitourinary Tumors)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Tirumotecan

Bladder cancer+2

Not yet recruiting

Long-Term Safety and Efficacy of aUroCell-Tx in Muscle-Invasive Bladder Cancer Patients Undergoing Neobladder Reconstruction – Extension Study

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AUROCELL-TX
  • Sponsor:Phosprint S.A.

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab54 clinical trialsNivolumab36 clinical trialsDapagliflozin25 clinical trialsMycophenolate Mofetil24 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.